Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Clinical Editorial

Official title: Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Summary: The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.

Conditions: Chronic Leukemia, Acute Leukemia, Myeloproliferative Disorders, Lymphoproliferative Disorders, Myelodysplastic Disorders

Study type: INTERVENTIONAL

Primary purpose: BASIC SCIENCE

Phases: NA

Enrollment: 250 (ESTIMATED)

Status: RECRUITING

Completion: 2026-07-28 (ESTIMATED)

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT07445984

Open Original Source More Feed Items

Related by Condition/Drug

PubMedRelated by Conditionleukemia

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Clinical Briefing

Clinical Editorial

Source Reference

Related by Condition/Drug

Tumour-like extramedullary hematopoiesis after multiple kidney transplants: case report and key di

Acute Myeloid Leukemia with Blasts Showing Mature Lymphoid‑Like Morphology: Diagnostic Case Report

Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial

Higher dietary antioxidants linked to lower odds of cervical cancer in NHANES analysis

MYC–MIZ1 Enhancer Complexes Regulate Neuroendocrine Identity in Small Cell Lung Cancer

Sertraline plus Carfilzomib Synergy Targets SSP-Active T-cell Malignancies via Cholesterol Dysregu